News In Brief: Cancer trials smashed by COVID-19; Little evidence on QOL with cancer drugs; Immune checkpoint inhibition no extra burden in COVID-19

Cancer trials smashed by COVID-19 COVID-19 appears to have led to a 60% decrease in oncology trial launches between 2019 and the onset of the pandemic in 2020. The study aggregated all phase 1 to 4 oncology trials of drugs or biological agents hosted on the RAVE clinical trial platform that opened for patient accrual ...

Already a member?

Login to keep reading.

© 2022 the limbic